# OnCo record paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009" ;
  schema:name "SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma"@en ;
  schema:description "Children with standard-risk hepatoblastoma were cured just as often with cisplatin alone as with cisplatin plus doxorubicin, and had far fewer severe side effects, so doxorubicin can be left out."@en ;
  schema:url <https://onco.cc/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa0810613>, <https://pubmed.ncbi.nlm.nih.gov/19846851/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa0810613> ;
  schema:datePublished "2009"^^xsd:gYear ;
  schema:author "Perilongo G, Maibach R, Shafford E, et al." ;
  onco:cancers <https://onco.cc/cancers/hepatoblastoma/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:trials <https://onco.cc/trials/siopel-3/> ;
  onco:journals <https://onco.cc/journals/nejm/> .